Literature DB >> 31882471

Loss of MTUS1 Expression Is Associated With Poor Prognosis in Patients With Gallbladder Carcinoma.

Jongmin Sim1, Yeseul Kim2, Hyungsung Kim2, Seongsik Bang2, Seungyun Jee2, Seongun Park2, Su-Jin Shin2, Kiseok Jang3.   

Abstract

BACKGROUND/AIM: Microtubule-associated scaffold protein 1 (MTUS1) acts as tumor suppressor in several cancer types. This study assessed the relationship between clinicopathological characteristics and expression of microRNA candidates based on MTUS1 expression in gallbladder cancer (GBC).
MATERIALS AND METHODS: MTUS1 expression was evaluated by immunohistochemical staining of tissue microarrays from 109 cases of GBC. The association of MTUS1 expression with clinicopathological factors was explored. Two microRNA candidates (miR-19a-3p, and miR-19b-3p), which were identified by a literature review and computational analysis, were assessed in GBC tissue samples by quantitative real-time polymerase chain reaction.
RESULTS: Low MTUS1 expression in GBC was associated with high histological grade, perineural invasion, lymphovascular invasion, high T-stage, advanced TNM stage, poorer disease-free survival, and poorer cancer-specific survival. No statistical association between MTUS1 expression and expression of microRNA candidates was observed.
CONCLUSION: MTUS1 may act as tumor suppressor and might be a potential biomarker for predicting prognosis in GBC. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  MTUS1 protein; gallbladder cancer; immunohistochemistry; microRNA; prognosis; real-time polymerase chain reaction

Mesh:

Substances:

Year:  2020        PMID: 31882471      PMCID: PMC6984102          DOI: 10.21873/invivo.11753

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  30 in total

1.  Clinical and Prognostic Significance of Neoplastic Spindle Cells in Gallbladder Cancer.

Authors:  Ryuta Midorikawa; Toru Hisaka; Hisamune Sakai; Yoriko Nomura; Yuichi Goto; Toshihiro Sato; Ryuichi Kawahara; Hiroto Ishikawa; Fumihiko Fujita; Masafumi Yasunaga; Masahiko Tanigawa; Yoshiki Naito; Jun Akiba; Hirohisa Yano; Hiroyuki Tanaka; Yoshito Akagi; Koji Okuda
Journal:  Anticancer Res       Date:  2019-08       Impact factor: 2.480

2.  Radiotherapy or Chemoradiation in Unresectable Biliary Cancer: A Retrospective Study.

Authors:  Silvia Bisello; Milly Buwenge; Andrea Palloni; Rosa Autorino; Francesco Cellini; Gabriella Macchia; Francesco Deodato; Savino Cilla; Giovanni Brandi; Luca Tagliaferri; Silvia Cammelli; Vincenzo Valentini; Alessio G Morganti; Gian C Mattiucci
Journal:  Anticancer Res       Date:  2019-06       Impact factor: 2.480

Review 3.  Molecular pathogenesis of gallbladder cancer: An update.

Authors:  Shravan Kumar Mishra; Niraj Kumari; Narendra Krishnani
Journal:  Mutat Res       Date:  2019-07-06       Impact factor: 2.433

4.  Structural organization and expression of human MTUS1, a candidate 8p22 tumor suppressor gene encoding a family of angiotensin II AT2 receptor-interacting proteins, ATIP.

Authors:  M Di Benedetto; I Bièche; F Deshayes; S Vacher; S Nouet; V Collura; I Seitz; S Louis; P Pineau; D Amsellem-Ouazana; P O Couraud; A D Strosberg; D Stoppa-Lyonnet; R Lidereau; C Nahmias
Journal:  Gene       Date:  2006-08-01       Impact factor: 3.688

5.  MTUS1 tumor suppressor and its miRNA regulators in fibroadenoma and breast cancer.

Authors:  Murat Kara; Mehmet Kaplan; Ibrahim Bozgeyik; Onder Ozcan; Ozgur Ilhan Celik; Esra Bozgeyik; Onder Yumrutas
Journal:  Gene       Date:  2016-05-04       Impact factor: 3.688

Review 6.  Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.

Authors:  Jason K Sicklick; Paul T Fanta; Kelly Shimabukuro; Razelle Kurzrock
Journal:  Cancer Metastasis Rev       Date:  2016-06       Impact factor: 9.264

Review 7.  MicroRNA aberrations: An emerging field for gallbladder cancer management.

Authors:  Vishal Chandra; Jong Joo Kim; Balraj Mittal; Rajani Rai
Journal:  World J Gastroenterol       Date:  2016-02-07       Impact factor: 5.742

8.  Down-regulation of MTUS1 in human colon tumors.

Authors:  Christina Zuern; Jutta Heimrich; Roland Kaufmann; Konrad K Richter; Utz Settmacher; Christoph Wanner; Jan Galle; Stefan Seibold
Journal:  Oncol Rep       Date:  2010-01       Impact factor: 3.906

9.  8p22 MTUS1 gene product ATIP3 is a novel anti-mitotic protein underexpressed in invasive breast carcinoma of poor prognosis.

Authors:  Sylvie Rodrigues-Ferreira; Anne Di Tommaso; Ariane Dimitrov; Sylvie Cazaubon; Nadège Gruel; Hélène Colasson; André Nicolas; Nathalie Chaverot; Vincent Molinié; Fabien Reyal; Brigitte Sigal-Zafrani; Benoit Terris; Olivier Delattre; François Radvanyi; Franck Perez; Anne Vincent-Salomon; Clara Nahmias
Journal:  PLoS One       Date:  2009-10-01       Impact factor: 3.240

10.  MTUS1/ATIP3a down-regulation is associated with enhanced migration, invasion and poor prognosis in salivary adenoid cystic carcinoma.

Authors:  Tingting Zhao; Xueqiang Ding; Boyang Chang; Xiaofeng Zhou; Anxun Wang
Journal:  BMC Cancer       Date:  2015-03-31       Impact factor: 4.430

View more
  3 in total

Review 1.  Epigenetic Regulations of Perineural Invasion in Head and Neck Squamous Cell Carcinoma.

Authors:  Pavel Hurník; Zuzana Chyra; Tereza Ševčíková; Jan Štembírek; Kateřina Smešný Trtková; Daria A Gaykalova; Marcela Buchtová; Eva Hrubá
Journal:  Front Genet       Date:  2022-04-27       Impact factor: 4.772

2.  MTUS1 is a promising diagnostic and prognostic biomarker for colorectal cancer.

Authors:  Lin-Yao Cheng; Mao-Sen Huang; Hua-Ge Zhong; Hai-Ming Ru; Si-Si Mo; Chun-Yin Wei; Zi-Jie Su; Xian-Wei Mo; Lin-Hai Yan; Wei-Zhong Tang
Journal:  World J Surg Oncol       Date:  2022-08-13       Impact factor: 3.253

Review 3.  Microtubule-Associated Protein ATIP3, an Emerging Target for Personalized Medicine in Breast Cancer.

Authors:  Maria M Haykal; Sylvie Rodrigues-Ferreira; Clara Nahmias
Journal:  Cells       Date:  2021-05-01       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.